V arious peripheral mediators contribute to development and maintenance of inflammatory and neuropathic pain by few mecha nisms. Activation or excitation of nociceptive nerve endings or fibers by these substances implicates generation of action potentials which were disseminated on the central nervous system and may induce pain perception. Sensitization of nociceptors occurs in response to various stimuli of external and internal origin, including temperature, mechanical and chemical influences. Bradykinin (BK) is one of the most potent pain-producing agents formed under inflammatory conditions. Multitude of its sensiti zing and excitatory effects on peripheral nociceptors supporting its role as a prototype of peripheral pain mediators have been described [1, 2, 6, 10] . A number of bradykinin effects mediated by products of the arachidonic acidcyclooxygenase cascade testify to the existence of mutual interactions between the pain mediators [12] . The synthesis of bradykinin and related kallidin is carried out in two ways: intravascularly in plasma and extravascularly in tissues. Prekallikrein formed through clotting factor XII (Hagemann) by formation of kallikrein predecessors that is activated by contact with negatively charged surfaces. Plasma kallikrein acts on high molecularweight kininogen that leads to bradykinin and kallidin producing which act preferentially on B 2 bradykinin receptors. The tissue prekallikrein is transformed to kallikrein upon inflammation or tissue damage. Today two types of bradykinin and related kinin receptors B 1 and B 2 , have been described [7, 9, 14, 16] . B 2 type present in the neurons of the brain stem, basal nuclei, cortex, thalamus and hypothalamus. Immune labels of these receptors were found in the endothelium of the upper sagit-tal sinus dura matter and ependyma of the third and lateral ventricles. B 1 kinin receptors are localized in neurons of the thalamus, hypothalamus and spinal cord [13] . B 1 and B 2 receptors are important mediators of cardiovascular homeostasis, inflammation and nociception. While the B 2 type is constitutively expressed in many tissues including smooth muscle of intestine and stomach [15] , B 1 type synthesis is induced only in inflammatory conditions. However, B 1 is one of the central nociceptive mediators feeling that suggest permanent presence of the receptor in the brain and spinal cord [4] . Bradykinin interaction with these receptors leads to activation of Gproteins and specific changes in the levels of [Ca 2+ ] cyt , involving in various systems such as phospholipase C, prostaglandins, protein kinases and phospholipase A 2 [8] . Natural and artificially synthesized receptor blockers are important for investigations of action mechanisms of agonists and antagonists of the kininkallikrein system. Search for high affinity and selective non-peptide antagonists that demonstrate prolonged effect and do not decompose in a body by peptidases is very important task for pharmacology and medicine.
B2receptors activation in smooth muscle of stomach can run it contraction as described above. Therefore, the model bradykinininduced contraction of the stomach smooth muscles is simple and informative to investigate the effect of different substances on the function of kallikreinkinin system. 1,4-Benzodiazepine derivatives are synthetic inhibitors that act as highly efficient analgesics. Biochemical properties of 3-substituted 1,4-benzodiazepine are determined by features of their chemical structure. Using radicals with different chemical and physical properties to obtain derivates of basis molecules we created some compounds with affinity for specific biological targets [11] . These substances can mimic the βbend that is important for their biochemical activity [5] . In addition, such compounds are well sustained by patients.
Previously synthesized in A. V. Bogatsky Physi coChemical Institute of NAS of Ukraine 3-substituted 1,4-benzodiazepin-2-ones exhibiting analgesic activity at doses ranging from 0.007 to 6.6 mg/kg were studied in this paper, some representatives of these series see in Table. These substances are perspective analgesics that have sedative, spasmolytic, antiinflammatory and low toxicity properties.
The existing today compounds that act through opioid receptors cause addiction. Nonsteroidal anti inflammatory drugs have many side effects, inclu ding contribution to the development of stomach ulcers. Compounds, used in our investigation, are deprived these effects.
In view of their low toxic and high analgesic activity, the aim of the study was to investigate influen ce of 3substituted1,4dihydro benzodiazepines on bradykinininduced smooth muscle contraction, as most simple and informative model for interactions of these compounds with kallikreinkinin system.
materials and methods
Tenzometric investigations were carried out using specimens ring stomach muscles of white nonbread male rats which were kept in the standard conditions in vivarium of Educational and Scientific Centre "Institute of Biology and Medicine" of Taras Shevchenko National University of Kyiv. All manipu lations with animals were carried out in accordance with the "European Convention for the protection of Vertebrate Animals Used for Experimental and other Scientific purposes" and the Law of Ukraine "On protection of Animals from Cruelty". Animal weight was 240260 g. Rats were rapidly decapitated; the stomach was isolated and washed with Krebs solution. Muscle layer from antral part of the stomach was separated from the serosa and mucosa and cut into strips (size -1.52 × 10 mm).
We used the next solutions:
• Krebs solution (mM/l): NaCl -120.4; KCl -5.9; NaHCO 3 -15.5; NaH 2 po 4 -1.2; MgCl 2 -1.2; CaCl 2 -2.5; glucose11.5; pH 7.4.
• HighK solution where 80 mM K + was used as initial inducer of contraction for test measurements. It was prepared by replacing sodium ions equimolar number of potassium ions in the Krebs solution.
Bradykinin solutions of specified concentrations were prepared by dilution of 1 mM bradykinin solution. Action of derivatives of 3substituted 1,4benzodiazepine on smooth muscles was evaluated using experimental model of bradykinininduced contraction of smooth muscle strips. Contraction of smooth muscles caused by application of bradykinin in concentration range 10 -10 -10 -5 M. The final concentration of 3-substituted derivatives of 1,4-benzodiazepine in the incubation solution was 10 -6 M. The bradykinininduced contraction of smooth muscle strips on background applications competitive inhibi tor of bradykinin receptor desarg9 [leu8] brady kinin acetate (10 -6 М) was studied for additional evaluation of the biological effects of derivatives of 3-substituted 1,4-benzdiazepines. As derivatives of 3-substituted 1,4-benzodiazepines we used the following compounds: MX 1775, MX2011, MX2004, MX1785, MX1626, MX1828, the structural formulas of which are presented in Table. All compounds were synthesized in A. V. Bogatsky PhysicoChemical Institute, NAS of Ukraine, Odesa.
Structural formulas and molecular weights of 3-substituted 1,4-benzdiazepines and analgesic activi ty (by the method of "acetic acid writhing")
Effectiveness of 3substituted 1,4benzodiaze pines on bradykinininduced contraction we evalua ted in percent by comparison with amplitude (mN) and maximal normalized rate (Vn) of contraction upon impact of bradykinin only.
Every substance of 3substituted 1,4benzodia zepines was tested on 10 separated smooth muscle strips.
Data processing on dynamics of contraction was performed according to the method of T. Burdyha and S. Kosterin [3] . Statistical analysis of experimental data was carried out using ShapiroWilk test for control of normality of distribution data. If the data did not have the normal distribution, the comparison was carried out by KruskalWallis indepen dent sample criterion. In case of normal distribution, comparison of control and experimental samples we used ANOVA (Scheffe test) (P < 0.05).
results and discussion
We analyzed the influence of 3substituted 1,4benzodiazepines on amplitude and rate of brady kinininduced smooth muscle contraction. The concentration range of bradykinin was 10 -10 -10 -6 M.
The presence of MX1775 in solution led to the statistically significant increase of Vn by 11.9% and decrease of amplitude by 13.1% (Fig. 1, A, B (Fig. 1, A) . However, the force of contraction linearly decreased for this range of BK concentration. There were no differences for 10 -6 M BK, but statistically significant decrease of amplitude by 22.2% was observed for 10 -10 M BK (Fig. 1, B) . MX2004 had no effect on Vn of contraction of smooth muscles induced by BK for all the concentration range (Fig. 1, A) . However, the force of contractions for bradykinin concentrations 10 -6 and 10 -7 М was statistically significantly reduced by 8.2%, 16.6%, respectively upon influence of MX 2004 (Fig. 1, B) . 
Fig. 1. Influence of 3-substituted 1,4-benzdiazepines on Vn (A) and force (B) smooth muscle contraction of rats stomachs (*P < 0.05). (Comparison with amplitude (mN) and maximal normalized rate (Vn) of contraction upon impact of bradykinin only (line "0"))

Fig 3. Influence of 3-substituted 1,4-benzdiazepines on Vn (A) and force (B) smooth muscle contraction of rats stomachs (*P < 0.05). (Comparison with amplitude (mN) and maximal normalized rate (Vn) of contraction upon impact of bradykinin only (line "0"))
concentration 10 -6 M, this parameter increases by 10.7% (Fig. 3, A) and amplitude is reduced by 29.5% (Fig. 3, B) .
MX2011 statistically significant decreased Vn smooth muscle contraction by 2025% for almost all used BK concentrations, but concentration 10 -9 M had weak effectiveness -14.9% (Fig. 3, A) . The force of smooth muscle contraction was decreased for bradykinin concentrations of 10 -6 and 10 -7 M with effects -16.7 and 28.1%, respectively, upon influence of MX2011 (Fig. 3, B) .
MX1785 demonstrated the reduced Vn smooth muscle contraction by 1015% for bradykinin concentrations of 10 -10 -10 -7 M. This parameter is not changed for 10 -6 M BK (Fig. 3, A) . Force smooth muscles contractions are decreased by 13.46% and 16.07% when BK concentration was 10 -6 and 10 -7 M, respectively. Contraction force was increased by 17% for BK concentration 10 8 M in presence of MX 1785 (Fig. 3, B) .
We have been analyzing insufficient number derivatives 3-substituted 1,4-benzodiazepines for demonstration of biochemical effect which depends on their structure. Preliminary assumptions are follo wing: substances MX2011 and MX2004 are similar in their effect due to the presence chlorine atom. Maybe similar effects of MX1785 and MX 1828 caused by structural factors.
So, analysis data show that two 3substituted 1,4benzodiazepines MX1775 and MX1828 demon- MX1775 and MX1626 statistically significant сhanged the Vn smooth muscle contraction (Fig. 1) like as inhibitor B 2 -receptor des-arg 9 bradykinin ace tate (Fig. 2) . These effects may evidence of interac tions of these compounds with bradykinin receptors or it signal transduction pathways.
MX1828 statistically significant decreased the normalized rate of smooth muscle contraction for bradykinin concentrations 10 -10 and 10 -9 M by 20.7 and 8.6%, respectively. Nevertheless, for agonist strate the similar inhibition effect on bradykinininduced contraction of smooth muscle like competitive inhibitor des-arg 9 bradykininacetate to bradykinin B 2 -receptors. These substances caused the increase of Vn of bradykinininduced contractions at 10 Биохимические свойства 3замещенных 1,4бенздиазепинов определяются особенностя-ми их химической структуры. Было проанализи-ровано влияние 3замещенных 1,4бенздиазепин 2онов на максимальную нормированную скорость и амплитуду изометрического сокра-щения гладких мышц крыс. Соединения МХ 1775 и МХ1828 проявляли ингибирующий эффект на брадикинининдуцированное сокра-щение гладких мышц, подобный такому как у конкурентного ингибитора В 2 брадикининовых рецепторов -desarg 9 bradykininacetate. МХ 1626 показал однонаправленные изменения максимальной нормированной скорости и силы сокращения гладких мышц, которые пропор-ционально зависели от диапазона концентра-ций брадикинина 10 -10 -10 -6 М. МХ1828 стати-стически достоверно уменьшал максимальную нормированную скорость сокращения при кон-центрациях брадикинина 10 -9 и 10 -10 М на 20,7 и 8,6% соответственно, но при 106 М данный показатель возрастал на 10,7% при уменьшении амплитуды на 29,5%. МХ2011, МХ1785 и МХ 2004 не проявляли закономерности влияния на брадикинининдуцированное сокращение. Со-единения МХ1775, МХ1828, МХ1626 могут быть отобраны для дальнейших исследований их влияния на кининкаликреиновую систему и болевую чувствительность гладких мышц.
К л ю ч е в ы е с л о в а : сокращение гладких мышц, брадикинин, 3замещенные 1,4бенздиазепин2оны, максимальная норми-рованная скорость, сила сокращения.
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